Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, et al. Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2024 Dec 7. doi: 10.1007/s10549-024-07551.
PMID: 39644403